Colette Aliman is a creative researcher working within the fields of Design and Art. In 2017 she moved from New York City to attend the Contextual Design Masters at Design Academy Eindhoven, The Netherlands. After graduation, in 2019, she launched the platform: Sonic Recalibration Lab to explore the soundscapes that we and other species find ourselves in as a result of the industrial revolution. In 2020, Colette Aliman and Lauriane Heim began their design research platform studiocalh.
Colette finds an intuitive relation to sound and translating complex scientific knowledge into design, a focus in all of her projects. Her topics of interest and research include multi-species-culture(s) sonic intersections, raising awareness of citizen’s choice in a product’s sound design, and speculative R&D in the future of the industrial revolution soundscapes. Her work advocates for the investigation of urban soundscapes through the methodology of intuitive recalibration.
Click here for the full CV
Contact
E-mail→emailcolette@gmail.com
Instagram→@colettealiman
© Colette Aliman 2021 All rights reserved.
Designed & Developed by June Park
|
Mutated Industry ×
Website→ covid.geodesign.online
COVID-19 is marking a re-structuring of the pharmaceutical landscape as nation states recognize a need for security and resilience within production processes. Heavily affected by the pandemic, the production of paracetamol slowed down significantly while demands grew due to the medication’s positive impact on symptoms of an infection with COVID-19. In response to the ongoing global pandemic, Mutated Industry points out how a highly confidential and ingrained pharmaceutical industry is developing resilient approaches to redesign its global supply chain. With a scenario set three years in the future, Mutated Industry explores strategies of total reshoring, the return of production back to the company’s original country, of a component critical for pharmaceutical production. A symphonic visual lecture, Mutated Industry addresses possible developments within a global pharmaceutical supply chain incited by disruptions caused by COVID-19. |
|
|---|